August 19th, 2009
A Canadian research study states that Avandia, used for the type 2 diabetes treatment, elevates the risk of heart failure and death more so than Actos.
Since 2007, Avandia has been the center of medical disagreement. On one hand, some medical professionals believe the drug is related to elevated risks of heart attack and death, where as others have disregarded these claims to some extent. In conjunction, however, many consider that the drug should not be used as a treatment option, considering the safer alternatives.
The study was conducted by lead researcher Dr. Juurlink, division head of clinical pharmacology and toxicology at Sunnybrook Health Sciences Center in Toronto. The team harvested data on 39, 736 patients who had been treated with either Avandia or Actos between April of 2002 and march of 2008. The data was then contrasted with heart failure, heart attacks and death hospital records.
As a result, the research team discovered that patients treated with Avandia were at a significant risk of heart failure and death than those patients treated with Actos. Interestingly, there was no notable difference between the drugs relating to risks of heart attack.